{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:12:45Z","timestamp":1787890365122,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00417-025-07001-6","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T08:41:16Z","timestamp":1762591276000},"page":"407-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy \u2013 a multicentre study"],"prefix":"10.1007","volume":"264","author":[{"given":"Nasiq","family":"Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz H.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul N.","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eichenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihteh","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Anetakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Sahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1772-3558","authenticated-orcid":false,"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"issue":"2","key":"7001_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","volume":"58","author":"B Nicholson","year":"2013","unstructured":"Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58(2):103\u2013126","journal-title":"Surv Ophthalmol"},{"key":"7001_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00443-2","volume":"9","author":"A Zarnegar","year":"2023","unstructured":"Zarnegar A, Ong J, Matsyaraja T, Arora S, Chhablani J (2023) Pathomechanisms in central serous chorioretinopathy: a recent update. Int J Retina Vitreous 9:3","journal-title":"Int J Retina Vitreous"},{"issue":"4","key":"7001_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2018.12.048","volume":"126","author":"S Mrejen","year":"2019","unstructured":"Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV et al (2019) Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology 126(4):576\u2013588","journal-title":"Ophthalmology"},{"issue":"5","key":"7001_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12052069","volume":"12","author":"S Caplash","year":"2023","unstructured":"Caplash S, Surakiatchanukul T, Arora S, Maltsev DS, Singh SR, Sahoo NK et al (2023) Multimodal imaging based predictors for the development of choroidal neovascularization in patients with central serous chorioretinopathy. J Clin Med 12(5):2069","journal-title":"J Clin Med"},{"issue":"8","key":"7001_CR5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1001\/jamaophthalmol.2015.1320","volume":"133","author":"MAB Filho","year":"2015","unstructured":"Filho MAB, de Carlo TE, Ferrara D, Adhi M, Baumal CR, Witkin AJ et al (2015) Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography. JAMA Ophthalmol 133(8):899\u2013906","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"7001_CR6","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00417-019-04297-z","volume":"257","author":"F Sulzbacher","year":"2019","unstructured":"Sulzbacher F, Sch\u00fctze C, Burgm\u00fcller M, V\u00e9csei-Marlovits PV, Weingessel B (2019) Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA). Graefes Arch Clin Exp Ophthalmol 257(8):1581\u20131590","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"7001_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.4103\/ijo.IJO_1238_18","volume":"67","author":"R Bansal","year":"2019","unstructured":"Bansal R, Dogra M, Mulkutkar S, Katoch D, Singh R, Gupta V et al (2019) Optical coherence tomography angiography versus fluorescein angiography in diagnosing choroidal neovascularization in chronic central serous chorioretinopathy. Indian J Ophthalmol 67(7):1095\u20131100","journal-title":"Indian J Ophthalmol"},{"key":"7001_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1272524","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhang J, Sun X (2022) The efficacy of anti-VEGF therapy for putative or visible CNV in central serous chorioretinopathy by optical coherence tomography angiography. J Ophthalmol 2022:1272524","journal-title":"J Ophthalmol"},{"issue":"5","key":"7001_CR9","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00417-020-04623-w","volume":"258","author":"B Schworm","year":"2020","unstructured":"Schworm B, Luft N, Keidel LF, Hagenau F, Kern C, Herold T et al (2020) Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents. Graefes Arch Clin Exp Ophthalmol 258(5):1013\u20131021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"7001_CR10","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R et al (2024) TENAYA and LUCERNE: Two-Year results from the phase 3 neovascular Age-Related macular degeneration trials of faricimab with Treat-and-Extend dosing in year 2. Ophthalmology 131(8):914\u2013926","journal-title":"Ophthalmology"},{"issue":"9","key":"7001_CR11","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S et al (2020) Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol 138(9):964\u2013972","journal-title":"JAMA Ophthalmol"},{"issue":"10326","key":"7001_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z et al (2022) Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 399(10326):741\u2013755","journal-title":"Lancet"},{"issue":"8","key":"7001_CR13","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"J Sahni","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC et al (2019) Simultaneous Inhibition of Angiopoietin-2 and vascular endothelial growth Factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology 126(8):1155\u20131170","journal-title":"Ophthalmology"},{"issue":"8","key":"7001_CR14","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C et al (2024) Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials. Ophthalmology 131(8):950\u2013960","journal-title":"Ophthalmology"},{"issue":"7","key":"7001_CR15","first-page":"825","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M (2022) Faricimab. First Approval Drugs 82(7):825\u2013830","journal-title":"First Approval Drugs"},{"issue":"17","key":"7001_CR16","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A (2023) The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study \u2013 6 month results. Eye 37(17):3574\u20133581","journal-title":"Eye"},{"issue":"1","key":"7001_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00586-w","volume":"10","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M (2024) Intravitreal faricimab for treatment na\u00efve patients with neovascular age-related macular degeneration: a real-world prospective study. Int J Retina Vitreous 10(1):70","journal-title":"Int J Retina Vitreous"},{"key":"7001_CR18","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.2147\/OPTH.S468458","volume":"18","author":"D Modeste","year":"2024","unstructured":"Modeste D, Stewart C, Premanandhan H, Awad MH, Williams GS (2024) Evaluating faricimab in treatment-naive neovascular age related macular degeneration: a retrospective analysis of real-world data. Clin Ophthalmol Auckl NZ 18:2821\u20132829","journal-title":"Clin Ophthalmol Auckl NZ"},{"issue":"7","key":"7001_CR19","first-page":"2113","volume":"65","author":"D Tabano","year":"2024","unstructured":"Tabano D, Ko S, Borkar D, Leng T, Ali F, Shaia JK et al (2024) Real-world clinical and anatomical outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with faricimab: the FARETINA-AMD study. Invest Ophthalmol Vis Sci 65(7):2113","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7001_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ajo.2024.08.040","volume":"269","author":"JT R\u00e4m\u00f6","year":"2025","unstructured":"R\u00e4m\u00f6 JT, Kim LA, Stryjewski T, Shah PP, Bejjani R, Brodie FL et al (2025) Targeting the Tie-2 receptor with faricimab in central serous chorioretinopathy: a case series motivated by a genetic finding. Am J Ophthalmol 269:246\u2013254","journal-title":"Am J Ophthalmol"},{"key":"7001_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58686-6","volume":"16","author":"JT R\u00e4m\u00f6","year":"2025","unstructured":"R\u00e4m\u00f6 JT, Gorman BR, Weng LC, Jurgens SJ, Singhanetr P, Tieger MG et al (2025) Rare genetic variation in PTPRB is associated with central serous chorioretinopathy, varicose veins and glaucoma. Nat Commun 16:4127","journal-title":"Nat Commun"},{"issue":"18","key":"7001_CR22","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","volume":"38","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD et al (2024) Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye 38(18):3569\u20133577","journal-title":"Eye"},{"issue":"1","key":"7001_CR23","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s41598-024-82746-4","volume":"15","author":"HY Han","year":"2025","unstructured":"Han HY, Park SM, Lee JH, Kim CG, Kim JW, Cho HJ et al (2025) Outcomes and predictive factors for fluid resolution following three loading injections of faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Sci Rep 15(1):938","journal-title":"Sci Rep"},{"key":"7001_CR24","doi-asserted-by":"crossref","unstructured":"Samac\u00e1-Samac\u00e1 D, Hern\u00e1ndez-Castillo C, Prieto-Pinto L, Rodr\u00edguez F, Sardi C, Ocampo H et al Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis. BMJ Open Ophthalmol [Internet]. 2024 Jul 23 [cited 2025 May 28];9(1). Available from: https:\/\/bmjophth.bmj.com\/content\/9\/1\/e001702","DOI":"10.1136\/bmjophth-2024-001702"},{"key":"7001_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/11206721251328097","author":"N Jones","year":"2025","unstructured":"Jones N, Gore C, Saedon H, O\u2019Donnell C, Mahmood S (2025) Efficacy of treatment with faricimab for patients with refractory nAMD. Eur J Ophthalmol. https:\/\/doi.org\/10.1177\/11206721251328097","journal-title":"European Journal of Ophthalmology. 2025;35(5):1695-1702."},{"issue":"1","key":"7001_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62559-1","volume":"14","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M et al (2024) One-year outcomes and safety assessment of faricimab in treatment-na\u00efve patients with neovascular age-related macular degeneration in Japan. Sci Rep 14(1):11681","journal-title":"Sci Rep"},{"issue":"4","key":"7001_CR27","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41433-024-03487-2","volume":"39","author":"A Patwardhan","year":"2025","unstructured":"Patwardhan A, Ali N, Law S (2025) Intravitreal faricimab in treatment-na\u00efve neovascular age-related macular degeneration: real-world outcome of 12-week extension after the loading dose from a UK centre. Eye 39(4):766\u2013770","journal-title":"Eye"},{"key":"7001_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40942-022-00418-9","volume":"8","author":"AA Szigiato","year":"2022","unstructured":"Szigiato AA, Antaki F, Javidi S, Touma S, Duval R, Cordahi G et al (2022) Risk factors for epiretinal membrane formation and peeling following Pars plana vitrectomy for primary rhegmatogenous retinal detachment, an OCT guided analysis. Int J Retina Vitr 8:70","journal-title":"Int J Retina Vitr"},{"key":"7001_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ajo.2024.08.008","volume":"269","author":"I Ben Ghezala","year":"2025","unstructured":"Ben Ghezala I, Gabrielle PH, Sibert M, Steinberg LA, Dautriche A, Arnould L et al (2025) Severe intraocular inflammation after intravitreal injection of faricimab: a single-site case series of six patients. Am J Ophthalmol 269:11\u201319","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"7001_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/IAE.0000000000004394","volume":"45","author":"A Montesel","year":"2025","unstructured":"Montesel A, Sen S, Preston E, Patel PJ, Huemer J, Hamilton RD et al (2025) Intraocular inflammation associated with faricimab therapy: one-year real-world outcomes. Retina 45(5):827\u2013832","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07001-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-07001-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07001-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:43:15Z","timestamp":1771573395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-07001-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7001"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-07001-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Eichenbaum is an investigator, consultant and speaker for Genentech. Lihteh Wu is a consultant and lecturer for Roche and Bayer, and consultant for Ocular Therapeutix. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board from all individual centres that participated in the study and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u00a0Informed Consent was waived in view of retrospective analysis of clinical and imaging data of patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}